Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States.Estimating the economic benefits of positive shifts in fibromyalgia severity: an exploratory analysis based on modeling of clinical trial data of pregabalin.Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study.Understanding the effects on HR-QoL of treatment for overactive bladder: a detailed analysis of EQ-5D clinical trial data for mirabegron.Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data.The direct medical costs of Huntington's disease by stage. A retrospective commercial and Medicaid claims data analysis.Modeling hard clinical end-point data in economic analyses.The application of economics concepts to stratified medicine--use of health economics data to support market access for stratified medicine interventions.Distribution and drivers of costs in type 2 diabetes mellitus treated with oral hypoglycemic agents: a retrospective claims data analysis.Right anterior thoracotomy aortic valve replacement is associated with less cost than sternotomy-based approaches: a multi-institution analysis of 'real world' data.Assessing the burden of illness from cervical dystonia using the Toronto Western Spasmodic Torticollis Rating Scale scores and health utility: a meta-analysis of baseline patient-level clinical trial data.A cost comparison of long-acting insulin analogs vs NPH insulin-based treatment in patients with type 2 diabetes using routinely collected primary care data from the UK.Key data elements for use in cost-utility modeling of biological treatments for rheumatoid arthritis.Medical management, costs, and consequences of Alzheimer's disease in Germany: an analysis of health claims data.Burden of illness for patients with non-dialysis chronic kidney disease and anemia in the United States: review of the literature.Using 'big data' to validate claims made in the pharmaceutical approval process.Cost-effectiveness of droxidopa in patients with neurogenic orthostatic hypotension: post-hoc economic analysis of Phase 3 clinical trial data.Identifying patients with cost-related medication non-adherence: a big-data approachClinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data.Medical cost, incidence rate, and treatment status of gastroesophageal reflux disease in Japan: analysis of claims data.The clinical and economic burden of significant bleeding during lung resection surgery: A retrospective matched cohort analysis of real-world data.Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data.Costs of haematological adverse events in chronic myeloid leukaemia patients: a retrospective cost analysis of the treatment of anaemia, neutropenia and thrombocytopenia in patients with chronic myeloid leukaemia.Economic burden of venous thromboembolism: a systematic review.Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia.Evaluating medical resource utilization and costs associated with thrombocytopenia in chronic liver disease patients.Elicitation of utility scores in Canada for immune thrombocytopenia treated with romiplostim or watch and rescue.Elicitation of health state utilities in neuroendocrine tumours.The burden of immune thrombocytopenia in adults: evaluation of the thrombopoietin receptor agonist romiplostim.Economic evaluation of dabigatran etexilate for the primary prevention of venous tromboembolic events following major orthopedic surgery in the Netherlands.Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Québec, Canada.Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma.Costs associated with adverse events in patients with metastatic renal cell carcinoma.Modelling the lifetime economic consequences of glaucoma in France.Feasibility of using administrative claims data for cost-effectiveness analysis of a clinical trialCosts and persistence of brimonidine versus brinzolamide in everyday glaucoma care: an analysis conducted on the UK General Practitioner Research Database.The influence of co-morbidities on prescribing pharmacotherapy for insomnia: evidence from US national outpatient data 1995-2004.Predicting time to nursing home placement based on activities of daily living scores--a modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil.Addressing shortfalls in TIA care in the UK: an economic perspective.Healthcare utilization changes in relation to treatment intensification with insulin aspart in patients with type 2 diabetes. Data from a large US managed-care organization.
P1433
Q30486907-3E609378-F352-4C15-B475-592804E45034Q30562231-E9119949-D68C-4921-ACC7-442AF0B118FEQ30594525-96EF74C0-EE30-4146-91EB-1AB56987F8D0Q30621224-BD871930-D8D1-4532-B09A-EF07CFD61F03Q30631546-5B25A43F-25F4-403B-AABC-6CC482C358F2Q30650807-560F5378-8035-4513-9406-925BABBED5A8Q30666671-C7A10F67-5105-47E2-830D-9388A2115719Q30782977-CA09C522-12A5-471A-B2CE-0DDE397CE96CQ30833078-C93FD767-A53B-433C-86E7-2E7E72DBFB29Q30841866-F3983523-8378-4C87-8414-DD5F97F88702Q30844795-998998B8-018C-471F-940C-62421E325A3CQ30871741-34F8C256-ACD7-44C7-949B-729A95B8A07AQ30881384-30131363-8A9B-40FE-8D73-B9E88F910194Q30895017-098361D0-81AF-4307-81C0-6A70544973E6Q30982319-A3F4044F-545F-4799-A560-A3DA3A6A1A93Q31019662-B6015E5E-85F9-45A1-80EC-9D5A029F0FF3Q31034217-99D42A1B-6C4F-42C1-B01D-7B26759F67BEQ31070358-63E6DF90-E313-4FC6-B426-11B34173B821Q31092020-0A21504F-EC4B-4E75-ADCD-DA0AED007F06Q31098671-862AC40E-3753-44DB-9DFA-8358E86CA5C4Q31105876-753F2A6D-DE2A-4CFA-B289-108A60163B45Q31142213-A06F3FA7-F87D-4324-8025-45FA776BED43Q33385407-C24C0D90-EC93-435D-8877-66D50296C804Q33393594-5EF9EB97-005E-4FD2-BECB-A825F247847FQ33394303-92B16649-2440-41B3-A631-B7957D3AF4F3Q33397621-CCF5ED2A-4BC8-4314-AFEE-2F91923256FCQ33398544-612B16C1-5192-4BAF-9015-BDFA7AE666D0Q33399892-1E217D12-CF36-4513-8A0D-EB0D04638F04Q33400919-896F8D78-4C3A-4D11-97EA-90422D75AD3EQ33401088-631206B4-A68E-4760-8E4F-19EB741E567EQ33404701-2A696B6E-9ECE-433A-9966-B614946EB8A8Q33410152-1023D355-35A2-453C-9BBD-8AABBB6C62ACQ33417009-B4807C2D-2D18-48DC-9AA5-AF47FEF0752BQ33446350-AE536703-7B03-4E63-B045-EB33DD216B53Q33446356-D52E7C1E-4646-43CB-8C74-B5D18A9E065FQ33446363-57B09830-F484-42A7-88AD-712567675B41Q33446367-ABB2ABFF-EDAF-4F0D-80D6-CA3F6CA1CE03Q33459417-D02E237D-D304-4099-9E3B-6E3E91335600Q33511001-FB0637DC-4CC2-4110-9B79-A2A2F3994949Q33517163-E723B93C-3BCB-4391-8B2B-180D59638525
P1433
description
journal
@en
revista científica
@es
rivista scientifica
@it
vědecký časopis
@cs
wetenschappelijk tijdschrift van Informa
@nl
wissenschaftliche Fachzeitschrift
@de
مجلة
@ar
वैज्ञानिक पत्रिका
@hi
name
Journal of Medical Economics
@ast
Journal of Medical Economics
@da
Journal of Medical Economics
@en
Journal of Medical Economics
@es
Journal of Medical Economics
@fi
Journal of Medical Economics
@fr
Journal of Medical Economics
@it
Journal of Medical Economics
@nb
Journal of Medical Economics
@nl
Journal of Medical Economics
@nn
type
label
Journal of Medical Economics
@ast
Journal of Medical Economics
@da
Journal of Medical Economics
@en
Journal of Medical Economics
@es
Journal of Medical Economics
@fi
Journal of Medical Economics
@fr
Journal of Medical Economics
@it
Journal of Medical Economics
@nb
Journal of Medical Economics
@nl
Journal of Medical Economics
@nn
prefLabel
Journal of Medical Economics
@ast
Journal of Medical Economics
@da
Journal of Medical Economics
@en
Journal of Medical Economics
@es
Journal of Medical Economics
@fi
Journal of Medical Economics
@fr
Journal of Medical Economics
@it
Journal of Medical Economics
@nb
Journal of Medical Economics
@nl
Journal of Medical Economics
@nn
P236
P243
P3181
P1055
P1058
P1144
2008212526
P123
P1250
P1277
P1476
Journal of Medical Economics
@en
P236
P243
P3181
P407
P571
1998-01-01T00:00:00Z